09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
19:46 , Nov 1, 2018 |  BC Innovations  |  Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
19:07 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Regeneron reports Phase II data for evinacumab in HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from an open-label, international Phase II trial in 9 patients with homozygous familial hypercholesterolemia (HoFH) showing that evinacumab (REGN1500) added to current lipid-lowering therapy reduced mean LDL-C from baseline...
22:26 , May 18, 2017 |  BC Innovations  |  Targets & Mechanisms

Degrading NASH

Inflammation is one of the primary drivers of non-alcoholic steatohepatitis (NASH), but decreasing inflammation without creating susceptibility to infection remains a challenge for the field. In Nature Medicine this month, a Chinese team described how...
05:39 , May 12, 2017 |  BC Week In Review  |  Clinical News

FDA grants Regeneron's evinacumab breakthrough therapy designation for HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA granted breakthrough therapy designation to evinacumab (REGN1500) to treat homozygous familial hypercholesterolemia (HoFH). The mAb targeting angiopoietin-like 3 (ANGPTL3) is in Phase II testing for the indication. Regeneron Pharmaceuticals...
18:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Ionis to spin out lipid company Akcea

Ionis plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) will invest $50 million in Akcea...
23:50 , Mar 27, 2017 |  BC Extra  |  Financial News

Ionis lipid spinout Akcea targets $100M IPO

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million, according to a regulatory filing. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN)...
23:22 , Jan 26, 2017 |  BC Innovations  |  Strategy

Deep roots

Regeneron Pharmaceuticals Inc . is starting to see the fruits of its experiment with Geisinger Health System to mine vast quantities of patient data for links between genotype and phenotype. Three years into the project,...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...